Disease Landscape and Forecast Insights

Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSCLC…

The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…

Malignant melanoma requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, immunotherapy, and small molecule-targeted therapies. Treatment decisions are influenced…

Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK…

Combination therapies are transforming the malignant melanoma treatment landscape, raising the efficacy bar for emerging therapies. However, combination therapies have increased the cost of…

This quarterly report series examines the current management of unresectable/metastatic malignant melanoma in the United States from the perspective of medical oncologists and explores trends in…

LaunchTrends: Keytruda Wave 3 (US) is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the malignant melanoma drug…

The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Since 2011, three immune checkpoint inhibitors and four BRAF- or MEK-targeted agents have gained…

TreatmentTrends®: Malignant Melanoma Q2 2015 (US) is the first in a series of reports that examines current trends in the management of unresectable or metastatic malignant melanoma from the…

LaunchTrends: Keytruda (Wave 2) is the second in a series of syndicated reports designed to track the physician perception, uptake, and competitive environment of the malignant melanoma drug…

Will the Emerging Immunotherapies and BRAF/MEK Inhibitor Combinations Meet Physicians’ and Payers’ Expectations? In recent years, several new, high-priced therapies have been approved for…

The poor prognosis of advanced malignant melanoma (melanoma) patients means that there is a significant need for effective therapies to treat patients in this indication and a large commercial…